Search
Personalized medicine promises radical improvements to healthcare in Europe
And the precision that personalised medicine will bring good prospects for better use of resources.
Read moreEHA Guidelines by Topic
AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…
“Nothing about us without us”: how patient advocacy is changing the game
Nuno Borges MBBS MRes, on behalf of YoungEHA
When it comes to advancing medical care, there is no denying that patients are at the core of everything we do.
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
Selected EMA news
September 2024Safety update
Withdrawal of Oxbryta (Voxelotor) – marketing authorisation suspended
Treatment of haemolytic anaemia (excessive breakdown of red blood cells) due to sickle cell disease
New medicines approved
Adzynma (rADAMTS13) - orphan medicine
Treatment of congenital thrombotic thrombocytopenic purpura (an inherited clotting disorder)
Other…